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The role of Notch receptors and ligands in health and disease 
ABSTRACT 
Notch signalling has an important role in the 
immune system in directing cell fate decisions in 
a range of diverse cell types. We are beginning to 
obtain a better understanding of the roles that 
the different Notch ligands and receptors play in 
both cellular differentiation of precursor cells and 
the regulation of immune responses by mature 
lymphocytes in the periphery. This review will 
examine the key findings that have emerged in 
relation to function of Notch in differentiation of 
T cells, B cells and dendritic cells and how 
modulation of Notch signalling seems to have 
potential for therapeutic applications in immune 
based diseases. 
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INTRODUCTION 
Notch signalling occurs between cells and is 
essential for embryonic development through its 
ability to regulate growth, differentiation and tissue 
patterning and in adults it is required for tissue 
homeostasis and stem cell self-renewal. Disruption 
to Notch signalling has been implicated with a 
range of human diseases including cancer, neuro-
degenerative diseases, and multiorgan congenital 
syndromes. The use of both gain-of-function and 
loss-of-function approaches to target specific 
receptors, ligands and downstream signalling 
effectors has lead to a better understanding of the
  
diverse roles for Notch signalling in the immune 
system. These studies have shed light on the role 
of individual receptor/ligand pairs that direct 
specific cell fate decisions in the immune system.  
In recent years there have been some excellent 
reviews written on the role of Notch signalling in 
the immune system [1-5] and in this review I 
would like to focus the discussion on the role of 
Notch receptors and ligands and their role in 
immune function concentrating more specifically 
on T cells, B cells and dendritic cells. 
Notch was first described in Drosophila melanogaster 
as a Type 1 transmembrane receptor protein that 
interacts with Type 1 transmembrane ligands: 
Delta and Serrate [6]. In mammals, four Notch 
receptors (Notch 1, 2, 3 and 4) can interact with 
five canonical Notch ligands of the Delta-Serrate-
Lag2 (DSL) family. Mammals express two 
Serrate-like ligands named Jagged1 and Jagged2 
and they differ structurally from the three Delta-
like ligands (Dll-1, -3 and -4). The Jagged ligands 
have more EGF-like repeats on their extracellular 
domain compared to the Dll ligands, and they also 
contain an additional cysteine -rich like region on 
the extracellular domain that is absent on the 
Delta-like ligands [7, 8]. Ligand binding to Notch 
receptors requires the cysteine-rich DSL domain 
together with the N-terminal domain (NTD) and 
the first two EGF-like repeats that physically 
interact with EGF repeats 11 and 12 on the Notch 
receptor [9]. The intracellular domain of the ligands 
do not display sequence homology but three of 
the five ligands (Jagged 1, Dll1 and Dll4) possess 
a PDZ (PSD-95/Dlg/ZO-1) domain on the C-
terminus that is thought to facilitate interactions 
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In turn, this RBP-Jκ -NICD-MAML complex 
alters the structure of chromatin into a form that is 
transcriptionally active. This results in transcription 
of Notch target genes such as NF-κB [17], 
members of the hairy enhancer of split (Hes) 
family such as Hes1 and Hes5 (beta helix-loop-
helix transcriptional repressors), Hes-related 
repressor protein 1-3 (HERP) [18, 19], Deltex1 
[20], c-myc [2], pTα and Meltrinβ [21], and PTEN 
[22]. Expression of Notch transcriptional targets 
in early T cell development such as Hes1 and 
Deltex1 mirror Notch1 expression, suggesting that 
Notch signalling accompanies Notch1 surface 
expression [23]. In addition to the classical RBP-
Jκ -dependent Notch pathway, there is also evidence 
for RBP-Jκ -independent Notch signalling [11]. 
The RBP-Jκ-independent pathway has been 
mainly characterized in Drosophila and exactly 
how it functions has not been clarified. 
 
Regulators of Notch signalling 
Notch signalling is also regulated by positive and 
negative regulators such as Deltex, Fringe, Numb, 
MAML, Presenilin1, Notch-regulated ankyrin-
repeat protein (Nrarp) and Msx interacting protein 
2 (Mint). A dominant-negative version of MAML1 
(DNMAML1) retains the ability to interact with 
NICD but does not potentiate transcriptional 
activation of Notch target genes [24]. Instead, 
DNMAML1 constructs can inhibit signalling by 
all four Notch1-4 receptors [25] by interrupting 
the recruitment of critical co-activators to the 
NICD/ RBP-Jκ complex, to inhibit transcriptional 
activation [26]. This is supported by an in vivo 
study revealing that expression of DN-MAML1 in 
the murine haematopoietic stem cells prevents T 
cell development and leads to B-cell development 
in the thymus [25]. Another negative regulator of 
Notch is Numb protein which antagonises the 
Notch signalling pathway by promoting the 
ubiquitination of the membrane-bound Notch1 
receptor and degradation of NICD domain 
following activation [27]. This in turn, blocks the 
nuclear translocation of Notch and downstream 
activation of Notch1 target genes [27]. 
 
Cis and trans signalling by Notch ligands 
Notch signalling is transmitted through interaction 
between Notch ligands on one cell (i.e. signal 
 
 
with the cytoskeleton PDZ ligand. The PDZ ligand 
of Jagged1 can mediate cellular transformation 
[10]. 
A number of non-canonical Notch ligands have 
been described in the literature and they represent 
a structurally diverse group of proteins that include 
integral membrane proteins (e.g. Dlk-1), GPI-
linked proteins (e.g. contactin 1 and 6) and 
secreted ligands (CCN3, MAGP-1 and MAGP2).  
None of these proteins have yet been described to 
have a function in the immune system and so are 
beyond the scope of this review. However, readers 
are referred to a recent review on this area by 
D’Souza et al. for more detail [11].  
 
Mechanism of Notch signalling 
Binding of a Notch ligand via the DSL domain 
to its receptor leads to a metalloproteinase-
dependent cleavage at S2 which lies in the 
extracellular portion of the N-terminal portion of 
transmembrane domain (NTM), creating a short 
lived membrane-bound form of NTM [12]. The 
final cleavage at site S3 catalysed by γ-secretase 
protease complex, releases the intracellular 
domain of the NTM (NICD) which translocates 
to the nucleus to form a short lived transcription 
complex by associating with a DNA binding 
transcription factor known as RBP-Jκ 
(Recombination signal Binding Protein or CSL 
(Core Binding Factor-1, Suppressor of Hairless, 
Lag1)) and transcriptional co-activators of the 
Mastermind-like family (MAML) [9]. This 
converts RBP-Jκ from a transcriptional repressor 
to an activator. NICD binds firstly to RBP-Jκ with 
high affinity through its RAM domain, which 
stabilises binding of ankyrin to RBP-Jκ. Ankyrin 
is absolutely required in all Notch functions 
because MAML does not bind free RBP-Jκ or free 
NICD but binds with high affinity to RBP-
Jκ/ankyrin binary complex [9]. Three MAML 
proteins have been identified [13, 14]. The C-
terminal domain of MAML binds to complexes 
containing RNA polymerase [15] and other 
histone acetyl transferase activity, including p300 
and pCAF [14-16]. Nuclear NICD is short-lived 
and degradation is promoted by phosphorylation 
of residues on the C-terminal end of the PEST 
domain [15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control of immune responses by Notch signalling 
trafficking of the Notch protein, while Rumi adds 
O-glucose to Notch and affects folding, stability 
or conformation in a temperature dependent 
manner [41-43]. In mammals POFUT1 is not 
required for surface expression of Notch receptors 
but it does appear to be important for ligand 
binding and efficient Notch signalling, but as yet 
there is no evidence for O-glucosyl modification 
of Notch receptors in mammals [44]. The addition 
of O-fucose to Notch EGF-like repeats is a 
prerequisite for the modification of Notch by the 
β1,3-N-acetylglucosaminyltransferase enzyme 
Fringe that adds N-acetylglucosamine to O-fucose 
residues [43, 45-48]. This additional posttranslational 
modification of the Notch receptor influences 
ligand binding by the receptor. Fringe modification 
of Notch promotes binding of the Delta ligands to 
the receptor and this may help facilitate Notch 
signalling when ligand concentrations are low. On 
the contrary Serrate/Jagged ligands are unable to 
bind to Fringe modified Notch receptors [49-51].  
Mammals express 3 different Fringe proteins 
Lunatic, Manic and Radical. The three enzymes 
are required during embryonic development and 
play important roles in tissue patterning [41]. In 
the immune system Lunatic Fringe is the enzyme 
that influences the Notch dependent process of 
T cell lineage specification in the thymus [52], 
while Lunatic and Manic Fringe are required to 
regulate Notch signalling in relation to the 
Marginal Zone B cell fate decision in the spleen 
[53] and these functions will be described in more 
later. 
 
Ligand endocytosis and signalling 
In Drosophila there is a requirement for both 
ligand and receptor endocytosis for efficient 
Notch signalling to occur and DSL ligands can 
follow two different rates after endocytosis 
[54-56]. Following ligand binding to the Notch 
receptor, the ligand needs to be internalized by the 
ligand expressing cell and it has been proposed 
that this interaction may provide a pulling force 
that leads to a conformational change in the Notch 
receptor exposing the S2 ADAM cleavage site. 
This events leads to the proteolytic release of the 
extracellular domain of Notch (NECD) and this 
can be shed or endocytosed by the DSL ligand 
expressing cells. Alternatively, endocytosis of 
sending cell) and Notch receptors expressed on a 
neighbouring cell (i.e. a signal receiving cell). 
This interaction in trans elicits a series of specific 
proteolytic cleavage events that culminate in the 
release of the intracellular domain of NICD [28] 
and signal transduction to the nucleus as described 
above. In mammals, both classes of Notch ligands 
(i.e. Jagged and Delta-like) can inhibit Notch 
signalling when expressed in the same cell as 
Notch; this phenomenon is referred to as cis- or 
cell autonomous inhibition of Notch signalling 
[8]. There is clear evidence from studies in 
Drosophila that cis-inhibition by DSL ligands 
controls a subset of Notch dependent developmental 
fates [29-32]. However, the physiological relevance 
of cis-signalling via Notch in mammals remains 
poorly understood. 
Truncated ligands that lack the intracellular 
domain of the ligand can act as effective 
inhibitors of Notch signalling that can disrupt 
tissue patterning during embryonic development 
in vivo [33-36]. Unlike the other canonical Notch 
ligands, the Dll3 protein lacks the conserved DSL 
domain as well as the key lysine residues in 
its C-terminal domain which are important for 
ubiquitination and association with PDZ domain 
proteins [37-39]. Several studies have shown that 
Dll3 is unable to activate Notch in trans but can 
function in cis-inhibition of Notch signalling 
[38-40]. Thus Dll3 appears to have evolved a 
divergent function compared to other canonical 
Notch ligands and therefore may assume a more 
regulatory role in controlling Notch signalling. 
The function of Dll3 in the immune system will 
be discussed further below. 
 
Regulation of Notch ligand binding by 
modification of glycosylation  
Notch receptors and ligands have conserved 
sequences in specific EGF-like repeats that can 
be modified with O- and N-linked glycans, in 
particular the O-fucose and O-glucose modifications 
mainly influence Notch signaling [41]. In 
Drosophila there are two enzymes located in 
the endoplasmic reticulum, O-fucosyltransferase-1 
(OFUT-1) and Rumi a glycosyl transferase, that 
both modify Notch with O-fucose and O-glucose 
respectively. OFUT-1 has both enzymatic and 
chaperone activities that promote folding and 
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The conditional deletion of Notch1 or RBP-Jκ 
within mouse lymphoid progenitor cells results in 
a marked decrease in thymus size with an early 
arrest of T cell development and a striking 
accumulation of intrathymic B cells (Radtke et al. 
1999). The failure of other Notch receptors to 
compensate for the loss of Notch1 suggests that 
Notch1 has a nonredundant role in T cell 
development in the thymus by directing lineage 
commitment of CLPs along the T cell rather than 
a B cell lineage [69, 70]. Notch2 and 4 are not 
obligatory for T cell commitment [71, 72], while 
Notch3 is required during the DN-DP transition of 
T cell development especially around the time of 
β-selection [71, 73]. The progression of thymocytes 
beyond the β-selection checkpoint requires the 
combined signalling of Notch and pTα and in 
particular Notch signalling enhances survival by 
modulating glucose metabolism [74, 75]. 
 
Role of DSL ligands in T cell development 
The thymus expresses both the Delta-like and 
Jagged ligands and these are largely restricted to 
stromal and epithelial cells [76, 77]. Using the 
OP9 stromal cell culture system it was thought 
that Dll1 and Dll4 were redundant in the thymus 
as ectopic expression of either Dll1 or Dll4 on 
OP9 cells was sufficient to support T cell 
development in vitro [78-80]. Animal studies have 
determined unequivocally that Dll4 is the major 
ligand directing T cell differentiation in the 
thymus. Conditional deletion of Dll4 but not Dll1 
in stromal cells leads to an early arrest of T cell 
differentiation and an accumulation of thymic 
B cells [81, 82]. The role of Jagged ligands 
in T cell development is less clear. OP9 stromal 
cells expressing Jag1 or Dll-1 inhibited the 
differentiation of DN1 thymocytes into B-cell 
lineage [80]. Unlike OP9- Dll1 cells which 
promote αβT cell maturation, Jagged1 failed to 
promote αβT cell maturation but instead favoured 
γδT cell development [80]. Likewise, the loss of 
Jagged2 does not affect T cell lineage 
specification and differentiation but Jagged2 
knockout mice displayed decreased numbers of 
TCRγδ+ cells in the thymus [83]. However the 
precise role of Jagged2 in this step of TCRγδ cell 
differentiation has yet to be resolved.   
DSL ligands is thought to direct ligands into an 
intracellular compartment where they can undergo 
posttranslational modification before being recycled 
to the cell surface where they can engage in 
receptor binding. Studies in Drosophila, Xenopus 
and Zebra fish have shown that endocytosis of the 
DSL ligand is directed by monoubiquitination of 
the cytoplasmic tail that requires the E3 ubiquitin 
ligases Neuralized and Mind bomb and these are 
critical for Notch signalling [57-61]. In mammals 
there are two genes encoding both classes of 
ubiquitin ligases Neuralized 1, 2 and Mind bomb 
1 , 2 and it appears that Mind bomb is the major 
E3 ligase required for ligand internalization [57, 
58, 62-65]. For a more thorough description of the 
role of endocytosis of Notch ligands and receptors 
the readers are directed to some comprehensive 
reviews written on this subject [7, 8]. 
 
Role of Notch in T cell differentiation                  
in thymus 
Notch signalling is important in haematopoeisis. It 
maintains a pool of self-renewing haematopoietic 
stem cells (HSC), uncommitted pool of lymphoid, 
myeloid and erythroid precursors in the bone 
marrow and is essential for the generation of 
definitive hematopoietic stem cells in early mouse 
embryos [66]. Notch signalling has a diverse role 
in the immune system as it can regulate the 
development and differentiation of T cells, B 
cells, monocytes, macrophages, dendritic cells, 
osteoclasts and natural killer cells [67]. The Notch 
signalling pathway is most studied and best 
understood in the earliest steps of T cell development. 
Common lymphoid progenitors (CLPs) travel form 
the bone marrow through the blood to seed the 
thymus. Notch1 is known to commit the common 
lymphoid progenitors into the T/NK cell lineage 
at the expense of the B cell, conventional and 
plasmacytoid dendritic cell lineages allowing 
efficient T ell specification [68]. Notch signalling 
is undetectable prior to the early T cell progenitor 
(ETP) stage and increases as the cells differentiate 
toward DN3 stage. At this stage, the cells must 
pass the ß-selection checkpoint, which requires 
two signals generated by the pre-TCR (pTα) 
complex and Notch1. Cells that receive these 
signals proliferate rapidly and following the 
success of ß-selection, the Notch signal is abruptly 
downregulated to slow down cell division [4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control of immune responses by Notch signalling 
(Th) cells is guided by specialised antigen 
presenting cells that are able to translate 
environmental signals to help stimulate an 
appropriate response to the antigen. CD4+ T cells 
were originally shown to differentiate along the 
Th1 and Th2 pathways that were defined by the 
specific patterns of cytokine secretion [85, 86].  
However this paradigm has shifted to incorporate 
the additional Th cell lineages that have been 
defined including Th17 cells, T follicular helper 
(Tfh) cells and adaptive or inducible regulatory 
T (Treg) cells [87]. The differentiation of CD4+ 
Th cells along the different lineages in vivo and  
in vitro is guided by the nature of the cytokines 
present within the immediate environment where 
T cell priming occurs and the expression of 
lineage specific transcription factors [87]. 
 
Notch and DC differentiation 
Antigen presenting cells such as dendritic cells 
(DCs) are crucial for T cell priming and there  
are two major subsets of DCs namely (i) 
conventional DCs (cDCs) and (ii) plasmacytoid 
DCs (pDCs) [88-90]. There are two types of cDCs 
which are referred to as resident cDCs and 
migratory cDCs. The resident CD8+ cDCs are 
found predominantly in T cell areas of lymphoid 
tissues, whereas the migratory CD8- cDCs reside 
in tissues and migrate to the regional lymph node 
following activation. The pDCs are characterized 
by their ability to secrete high levels of type 1 
interferon in response to viral infection and 
precursors are found in the peripheral blood and 
upon activation can migrate to nonlymphoid 
tissues at sites of chronic inflammation [88, 91]. 
There have been conflicting reports for the effect 
of Notch signalling on DC differentiation. Culturing 
bone marrow progenitors with GM-CSF and 
Dll1 can promote the differentiation of DCs 
[92]. Similarly culturing human blood monocyte 
derived precursors in the presence of the Dll1 
ligand and the cytokines GM-CSF and IL-4 can 
promote their differentiation into DCs and 
Langerhans cells [92]. DC differentiation is 
impaired in Notch1 antisense mice and conditional 
deletion of RBP-Jκ in bone marrow cells results in 
the loss of the CD8- migratory DCs that reside in 
the marginal zone of the spleen but there was a 
corresponding increase in pDCs in these animals 
Fringe is an important modulator Notch signalling 
through posttranslational modification of Notch 
receptors. Fringe modified Notch receptors favours 
the binding of the Delta ligands at the expense of 
Jagged/Serrate ligands [49]. Overexpression of 
Lunatic Fringe provides thymocytes with a 
competitive advantage in vivo promoting T cell 
lineage commitment compared to Notch1+/- cells. 
This finding can now be reconciled with the 
known role for Dll4 ligands in directing T cell 
differentiation, as Fringe modified Notch receptors 
on thymocytes should bind more avidly to Dll4 
ligands expressed on stromal cells to allow these 
cells to enter cellular niches where they can 
contact the ligands and cytokines for their survival 
and differentiation [52]. Endocytosis of Notch 
ligands is important for T cell development as the 
E3 ubiquitin ligase Mind bomb 1 is essential in 
cortical epithelial cells to induce Notch signalling 
in response to ligand binding by the Notch1 
receptor expressed by thymocytes [84].  
While most studies have focused on the role of 
Notch ligands expressed on stromal cells, a recent 
study revealed that Dll3 is expressed by 
thymocytes and is important in regulating Notch 
signalling in thymocytes. Dll3 is not required for 
T cell lineage specification but it does appear to 
help attenuate Notch signalling in DP cells [40].  
In the absence of Dll3 there is an increase in 
mature T cells that are exported from the thymus 
and these cells enter the peripheral circulation. 
The loss of Dll3 does not affect negative selection 
of DP cells but it does lead to enhanced positive 
selection of DP thymocytes leading to production 
of mature CD4+ and CD8+ T cells [40]. This was 
the first reported study of Dll3 function in the 
immune system and showed that Dll3 acts cell 
autonomously in thymocytes to regulate Notch 
signalling. Since Dll3 does not activate Notch in 
trans it suggests that Dll3 may act in cis-
inhibition but the exact mechanism of how this 
occurs has yet to be determined [40]. 
 
Role of Notch in regulation of peripheral 
immune responses 
The induction of immune responses to foreign 
antigens is dependent on the coordinated 
responses of both the innate and adaptive immune 
systems. The differentiation of CD4+ T helper 
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response to LPS stimulation and can promote Th1 
cell differentiation, whereas  in response to LPS 
CD8+ DCs, which reside in the T cell areas of the 
lymphoid tissues, upregulate IL-12 in a MYD88 
dependent fashion but do not express Dll4 [101, 
102]. Murine DCs treated with multiple TLR 
agonists specific for TLR2/4 (LPS), TLR5 
(Flagellin) and TLR9 (CpG) could induce 
expression of Dll4 in DCs whereas Dll1 and 
Jagged 1 was not affected by the same treatment 
[103]. Murine pDCs have been shown to 
constitutively express high levels of Dll4 and 
when they present antigen to Th1 cells can induce 
IL-10 secretion during T cell priming both in vitro 
and in vivo [104].  Human DCs appear to respond 
in a similar way to TLR signals to that observed 
by murine DCs. Immature human DCs express 
Jagged 1 but do not express Dll4. However 
following stimulation with TLR agonists to TLR3 
and TLR8 this lead to robust induction of Dll4 
expression but had minimal effect on Jagged 1 
expression. These TLR stimulated DCs expressing 
Dll4 could also induce Th1 responses [105]. 
Ectopic expression of Dll1 on allogeneic APCs 
could induce long lasting immune tolerance to 
cardiac allografts in mice [106]. Regulation in this 
model was mediated by CD8+ T cells that when 
activated in vitro could induce IFN-γ and IL-10 
secretion [106]. A similar pattern of co-expression 
of IFN-γ and IL-10 has also been observed with 
CD4+ Th1 cells recognizing antigen in the 
presence of Dll4 ligand on DCs [103]. Recent 
studies have confirmed the immunoregulatory role 
of Notch signalling in alloreactive T cells and that 
intervening in this pathway may be beneficial  
in inducing tolerance to alloantigens in vivo 
[106-108]. It has been proposed that antigen 
recognition by Th1 cells in the context of Dll4-
signalling on DCs can produce IL-10 secreting 
cells and this may allow the diversion of the 
immune response from an inflammatory to 
regulatory activity [103].   
 
Th1 and Th2 responses 
Dissecting the role of Notch signalling in the 
regulation of peripheral immune responses is 
made difficult due the large number of Notch 
receptors and ligands that can be expressed by 
peripheral T cells as well as the diversity of 
[93]. On the other hand conditional deletion of 
Notch1 was shown not to have any effect on 
thymic DCs or on cDCs or Langerhans cells or 
pDCs [94, 95]. 
ES cells that lack Notch1 have an impaired ability 
to differentiate as DCs [96]. To investigate the 
relationship between Notch and DC differentiation 
further, Zhou et al. [97] showed that Dll1-
mediated Notch signalling in HPCs can direct the 
differentiation of cDCs via activation of the Wnt 
signalling pathway. Culturing Notch1 deficient 
ES cells with Wnt ligands can restore cDC 
differentiation indicating that Wnt must be a 
downstream target of Notch signalling. Dll1 
facilitates Wnt signalling in HPCs by inducing 
expression of the Frizzled proteins which are the 
receptors of Wnt ligands [97].  
 
Notch ligands expressed by DCs and immune 
regulation 
During their circulation in nonlymphoid tissues 
and blood, DCs display an immature phenotype 
but following recognition of microbial antigens 
through pattern recognition receptors such as the  
Toll-like receptors (TLRs), NOD-like receptors or 
C-type lectins, DCs become activated and migrate 
to draining lymph nodes where they present 
peptide/MHC complexes to stimulate antigen-
specific naïve T cells.  Naive T cells need to make 
stable contacts with DCs in the lymph node  to 
achieve activation and the nature of cell surface 
ligands expressed by DCs at the time of antigen 
priming as well as the cytokines that are present 
will be determine the outcome of the immune 
response and will influence T effector cell 
differentiation [90, 98, 99]. Therefore DCs are 
well placed to directly impact the process of CD4+ 
and CD8+ T cell differentiation in vivo.  
TLR ligands are an efficient means of directing 
maturation of DCs but these innate signals can 
also influence Notch ligand expression on APCs.  
The response of bone marrow derived DCs to LPS 
has been shown to be rely on RBP-Jκ-dependent 
signalling through Notch [100]. Inhibiting Notch 
signalling in BM DCs prevented the up regulation 
of MHC II expression, reduced their mobility 
and their antigen presenting capacity to T cells 
[100]. The CD8- DCs upregulate Dll4 ligand in
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control of immune responses by Notch signalling 
immunoprecipitated from the HS5 Il4 enhancer 
and Notch/RBP-Jκ complexes were also detected 
bound to the upstream GATA-3 promoter in CD4+ 
Th cells [118]. Amsen and colleagues identified 
that culturing RBP-Jκ deficient and Notch1/Notch2 
deficient CD4+ T cells could still give rise to IL-4 
secretion in vitro, but when allowed to differentiate 
in vivo following antigen priming, Th2 cell 
differentiation was completely blocked [112].  
This discrepancy highlights important differences 
between in vitro and in vivo systems and that the 
in vitro polarizing culture conditions used by 
many laboratories around the world appear to 
override the Notch signal that would normally 
regulate Th2 differentiation.  
Previous studies have shown that stimulation of 
Th1 cells with IL-12 or IL-27 can induce IL-10 
production without affecting IFN-γ secretion 
[119-121]. The Dll4 mediated IL-10 secretion by 
of Th1 cells requires the presence of either IL-12 
or IL-27 and is mediated by STAT4 signalling 
and IL-10 induction could be blocked by the 
treatment of the γ-secretase inhibitor indicating 
that induction of IL-10 secretion is mediated by 
the canonical Notch signalling pathway[103]. 
pDCs that constitutively express Dll4 ligand can 
promote IL-10 secretion by Th1 cells in vitro 
[104]. Therefore this may be an important mechanism 
for immune regulation in vivo mediated by Notch 
signalling. Ectopic expression of Jagged ligands 
on DCs can promote Th2 immunity but there is 
also evidence that Jagged ligands can also directly 
influence the development of regulatory T cells 
in vivo. 
The requirement of Notch signalling in human 
CD4+ Th cell differentiation has not been clearly 
resolved. Using an RNAi knockdown approach 
Stallwood et al. examined the role different 
ligands in both human monocyte derived DCs  
and CD4+ T cells [122]. They found that the 
knockdown of specific ligands in DCs enhanced 
IFN-γ production by alloreactive CD4+ T cells.  
Knockdown of the Dll1 ligand in human CD4+  
T cells enhanced IFN-γ, IL-2 and IL-5 production 
following stimulation with anti-CD3/anti-CD28 
antibodies while knockdown of either Jagged 1 
or Jagged 2 ligands had no effect on cytokine 
production by human CD4+ T cells [122].  
Treatment of CD4+ T cells in this model system 
experimental systems that have been employed 
to address this issue. Antigen presenting cells 
expressing Jagged 1 or Dll1 ligands give rise to 
distinct responses following priming. Antigen 
recognition in the context of the Dll1 ligand can 
induce Th1 responses whereas recognition in the 
presence of the Jagged1 ligand on APCs induces 
Th2 responses [109-111]. The role for Notch 
signalling in Th1 cell differentiation is less 
compelling compared to that of Th2 cell 
differentiation.  Genetic inactivation of Notch1 
alone, or the deletion of both Notch1 and Notch2, 
RBP-Jκ or the transgenic expression of the 
DNMAML1 in CD4+ T cells did not affect Th1 
cell differentiation [109, 112-114] . T cells in each 
of these mouse strains were able to maintain 
robust IFN-γ secretion a hallmark of Th1 
immunity. However several studies have 
described that Notch signalling can favour Th1 
cell differentiation.  Antigen presented by Dll1 
expressing APCs could direct Th1 cell 
differentiation; ectopic expression of Notch1 ICD 
or Notch3 ICD in CD4+ T cells could promote 
Th1 cell differentiation; or treatment of CD4+ 
T cells with the γ-secretase inhibitor GSI could 
inhibit Th1 differentiation in vitro [115, 116].  
However if Notch does have a role in Th1 
differentiation it would appear from the gene 
knockout studies that this would have to be 
independent of the canonical Notch signalling 
pathway involving RBP-Jκ [109, 112, 113]. 
There is evidence in Drosophila that RBP-Jκ 
independent signalling can occur downstream of 
Notch, but this pathway remains poorly defined.  
In contrast abrogation of Notch signalling in 
CD4+ T cells prevented Th2 differentiation in 
mice primed with various Th2 polarizing antigens 
such as nematode infection or protein antigens 
immunized in alum adjuvant. The loss of Notch 
signalling lead to decreased secretion of IL-4  
and a failure to upregulate GATA-3 the master 
regulator of Th2 cell differentiation, whereas  
IFN-γ secretion was unaffected [109]. Supporting 
the role for Notch signalling in Th2 cell 
differentiation APCs expressing Jagged ligands 
can favour Th2 responses in vivo [109, 111, 117]. 
Molecular studies have identified that both 
Il4 and Gata3 are direct Notch target genes in 
CD4+ T cells [109, 118]. Notch and RBP-Jκ were
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responses. In more recent years it has become 
apparent that the function of TGF-β in the 
immune system is more pleiotropic and its 
influence on CD4+ T cell differentiation depends 
on the types of cytokines that are present at the 
time of T cell priming.  Naïve T cells activated in 
the presence of TGF-β and IL-6 can switch on the 
transcription factor ROR-γτ and differentiate to 
become Th17 cells which are involved in bacterial 
immunity at mucosal surfaces. When T cells 
encounter TGF β alone, this can induce Foxp3 
expression and direct iTreg development [126-
129]. In contrast, the presence of IL-6, antagonizes 
Foxp3 expression by a direct affect on serine 
threonine kinase AKT [130]. TGF-β signalling by 
the TGF-βIIR leads to the phosphorylation of 
Smad2/3 which forms a complex with Smad4 and 
this complex is translocated to the nucleus to 
regulate transcription of target genes. One of the 
targets is Smad7 which is an inhibitory Smad used 
to attenuate TGF-β signalling by competing with 
Smad 2/3 competes for binding to the receptor 
[131, 132]. 
 
Notch ligand expression on APCs and iTreg 
development  
It is more than 10 years since the first report that 
Notch ligands expressed on APCs could influence 
the outcome of a peripheral immune response. 
Hoyne et al. showed that ectopic expression of 
Jagged 1 on spleen DCs presenting allergen-
derived peptides could inhibit immune responses 
to the house dust mite allergen Der p 1 [133]. The 
suppression was long lasting and was transferable 
to naïve recipient animals via CD4+ iTreg cells in 
an antigen-specific manner [133]. These findings 
have been corroborated by several studies 
suggesting that Jagged ligands expressed by APCs 
favour iTreg cell differentiation in CD4+ T cells in 
both mouse and human culture systems [134-137]. 
Injection of Jagged2 expressing haematopoietic 
cells into nonobese diabetic (NOD) mice lead to 
the expansion of iTreg cells in vivo and these cells 
could decrease the incidence of spontaneous type1 
diabetes in NOD mice recipients. The induction 
of iTregs cells in this system could be inhibited 
by the addition of neutralizing antibodies to 
either Jagged2 or Notch3 dependent manner and 
suppression by Treg cells required cell-cell contact 
that was independent of TGFβ [135]. 
 
with a γ-secretase inhibitor did not influence 
cytokine production indicating that the Dll1 
modulation of cytokine secretion in human T cells 
occurs by a CSL independent pathway [122]. 
These studies would suggest that there are 
potential implications for modulation of Notch 
signalling in ligand expressing cells through 
expression of the ligands which may be 
reminiscent of cis-inhibition. The canonical Notch 
ligands Delta and Serrate can both function in 
cis-inhibition of Notch when expressed in the 
same cell. 
Regulatory T cells  
Autoimmunity arises following a failure in either 
central or peripheral tolerance mechanisms and is 
mediated by Th1 and Th17 responses that can 
give rise to either organ specific or systemic 
autoimmune diseases. In the periphery the immune 
system has a range of mechanisms available to 
control the fate of autoreactive T cells, including 
immune privilege, immune ignorance, activation 
induced cell death, clonal anergy and immune 
suppression mediated by regulatory T (Treg) cells. 
Regulatory CD4+ T cells play a central role in 
maintaining immune homeostasis to limit aberrant 
responses to antigen by effector T cells to both 
self and foreign antigens but the control of 
immune responses to these different antigens is 
mediated by distinct group of Treg cells [87, 123-
125]. Natural Treg cells arise in the thymus during 
T cell differentiation they express the winged 
helix transcription factor Foxp3 and differentiate 
to become mature cells with suppressive function.  
Once they enter the peripheral circulation they can 
circulate through lymphoid tissues and act to 
suppress immune responses to self antigens 
through both cell contact and through the 
secretion of inhibitory cytokines such as IL-10 
and TGFβ. Inducible Treg (iTreg) cells differentiate 
from naïve CD4+ CD25- cells when activated 
through their TCR in the presence of TGF-β and 
IL-10. These cells can also express Foxp3 and 
differentiate as an iTreg cell that can suppress the 
response of naïve CD4+ effector T cells through 
a mechanism that relies on the secretion of 
inhibitory cytokines such as IL-10, TGF-β or 
IL-35 [123].  
The immunoregulatory cytokine TGF-β plays an 
important role in dampening T cell proliferative
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control of immune responses by Notch signalling 
Notch and TGF-β iTreg effector function was 
further explored by Asano et al. who showed that 
Tregs can express Notch ligands, Jagged1 and 
Dll4, and that blockade of Notch signalling can 
inhibit the suppressive function of Tregs[143]. 
The NICD can interact with phospho-SMAD3  
and promote its translocation to the nucleus where 
it can modulate the expression of TGF-β target 
genes. Furthermore culturing CD4+ T cells in the 
presence of TGF-β and Dll4 could inhibit iTreg 
differentiation in vitro by inhibiting Jak3 induced 
Stat5 phosphorylation which is required for Foxp3 
expression [134, 144]. At present there is no 
definitive knowledge about the specific receptor- 
ligand pairs that are required to mediate Treg 
differentiation in vivo. Jagged ligands appear to 
favour iTreg differentiation but the precise Notch 
receptor involved in this process has not been 
resolved and may be either Notch1 or Notch3 
[143, 145, 146]. Further studies using conditional 
knockouts of these genes are required to resolve 
this issue. 
The current view is that the Delta-like ligands 
are strong inducers of Th1 immunity and to 
demonstrate the functional relevance of Notch 
signalling on immune regulation in vivo different 
experimental models have been used to study 
the effect blockade of Notch signalling on the 
outcome of disease pathogenesis. Experimental 
allergic encephalomyelitis (EAE) is an autoimmune 
inflammatory disease of the central nervous 
system in mice mediated by Th1/Th17 cells.  
Blockade of Dll4 on APCs during the induction 
phase of EAE reduced the clinical severity of the 
disease and was associated with an expansion of 
CD4+ Treg cells in the periphery and the CNS 
[134, 144, 147]. Modulation of Notch signalling 
has been attempted in a variety of Th2 animal 
models. Firstly, aerosol delivery of allergens can 
induce allergic sensitization and a Th2 mediated 
disease in the airways. Administration of an anti- 
Dll4 antibody during a period of allergic sensitization 
in mice exacerbated the development of allergic 
airway disease. Mice treated with an anti-Dll4 
antibody showed evidence of increased airway 
hyper-reactivity and mucus production [148]. 
Pharmacological blockade of Notch signalling 
using a γ-secretase inhibitor in vivo during allergic 
sensitization was capable of reducing Th2 mediated 
 
 
Mouse and human T cells appear to have different 
preferences for the Notch ligands required to 
induce Treg differentiation, as a recent report 
highlighted that the Dll1 ligand can induce 
differentiation of human CD4+ Foxp3+ Treg cells 
in vitro from CD34+ cord blood haematopoietic 
progenitor cells grown on OP9-Dll1 stromal cells 
[138]. It is important to note that the effect of 
Notch signalling on Treg differentiation appears 
restricted to the iTreg population and does not 
affect nTreg differentiation. Blockade of Notch 
signalling by conditional deletion of Notch 
receptors, RBP-Jκ signalling, or the expression of 
the DNMAML1 transgene in CD4+ T cells, does 
not affect the development or differentiation of 
the nTreg cells in the thymus and these animals 
show no evidence of spontaneous autoimmunity 
suggesting nTreg development and homeostasis 
must be normal despite the absence of Notch 
signalling [70, 71, 112, 114, 118]. 
 
Notch and TGF−β signalling in iTreg 
development 
The induction of the master regulator gene Foxp3 
is critical for CD4+ Treg development and it 
appears that Foxp3 is a target gene of Notch 
signalling in CD4+ T cells [139]. Expression of 
the constitutively active NICD gene can induce 
expression of a Foxp3 promoter and the NICD-
RBP-Jκ complex has been immunoprecipitated 
from the Foxp3 promoter in T cells [140]. Samon 
et al. showed that treatment of CD4+ T cells with 
the γ-secretase inhibitor could block the induction 
of TGF-β-induced Foxp3 expression in CD4+ T 
cells and the differentiation of Treg cells [141]. 
Likewise, blockade of Notch1 signalling in CD4+ 
T cells could prevent TGF-β mediated induction 
of iTreg differentiation in vitro. Collectively these 
studies showed that Foxp3 is a direct target of 
Notch signalling and this was further supported by 
animal studies which showed that blockade of 
Notch1 in vivo reversed the immunosuppressive 
effect of CD4+ Foxp3+TGF-β+ cells in allergic 
airway inflammation in mice. The iTregs cells in 
this model expressed membrane bound TGF-β 
and this was crucial to induce Notch signalling 
in target cells [142]. Soluble TGF-β is unable 
to induce Notch signalling even though it can 
induce STAT3 signalling. The relationship between
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Gerard F. Hoyne 
to T cells [161] and human anergic T cells [162].  
Genetic deletion of Dtx1 does not affect T cell 
development which is surprising given that it is a 
downstream target of Notch signalling [20, 161, 
163]. Loss Dtx1 prevents induction of Cbl-b 
expression during T cell anergy and Dtx1 deficient 
mice display a mild splenomegaly and T cells are 
hyperproliferative in vitro compared   to wild type 
T cells when stimulated with anti-CD3 and anti-
CD28. The mice also produce spontaneous auto-
antibody formation and exhibit pulmonary 
inflammation suggesting a defect in immune 
regulation that leads to spontaneous autoimmunity 
[161]. The data implies that Dtx1 plays an 
important role in dampening TCR signalling and 
is another E3 ligase that plays an important role in 
the induction of T cell anergy to control the fate 
of effector T cells [164-166]. 
 
Marginal zone B cells 
B cell development occurs in the bone marrow 
from CLPs that progress through a well defined 
differentiation process characterized by the 
expression of different cell surface and intracellular 
proteins [167, 168]. Three populations of mature 
B cells migrate exist in the periphery that reside 
in distinct anatomical locations and display 
distinct physiological roles. B1 B cells are found 
primarily in pleural and peritoneal cavities and 
are thought to provide an important response to 
bacteria and provide humoral immunity against 
invading gut pathogens. B2 follicular B cells 
circulate through the blood and spleen and are the 
predominant type of B cell found in lymph nodes 
[167-169]. They localize adjacent to the T-cell 
enriched areas of lymphoid tissues and respond to 
T-dependent antigens where they form germinal 
centres to help generate high affinity antibodies an 
undergo isotype switching. B2 Marginal Zone 
(MZ) B cells take up residence in the marginal 
sinus in the marginal zone of the spleen. MZ B 
cells are also thought to contribute to immunity 
to bacterial pathogens as they respond to 
T-independent antigens [167-169]. 
A further step of B cell maturation occurs in the 
spleen and progresses through two transitional 
stages defined as Type 1 (T1) and Type 2 (T2) 
and these help to give rise to the MZ B cells and 
follicular B cells in the spleen. T1B cells represent
  
airway hyperreactivity [149]. In addition treatment 
of mice with an anti-Dll4 antibody could block 
the development of allergic conjunctivitis in 
mice [150]. Finally treatment of mice with an 
antibody to Dll4 could also alleviate symptoms 
of respiratory syncytial virus infection a Th1 
mediated disease. The virus specific effector 
CD4+ T cells that emerged following anti-Dll4 
treatment displayed a Th2 phenotype and an 
increase in activated CD8+ T cells in the lung 
[151]. 
 
T cell anergy  
T cell activation is dependent on the delivery of 
two separate signals. Signal one is mediated 
through the TCR and the second signal is through 
the costimulatory receptor CD28 in response to 
binding of its ligands CD80/CD86 which leads 
phosphorylation of a number of intracellular 
signalling pathways including phospholipase γ-1, 
protein kinase-θ, MAPK, JNK, PI3K and Iκ-B 
kinase (IKK) that leads to the recruitment of 
transcription factors (e.g. NFAT, AP-1 and NF-
κB) critical to the transcription of the Il2 gene 
[152]. Ligation of TCR on T cells in the absence 
of CD28 costimulation leads to the development 
of clonal anergy which is characterized by the 
failure to activate the MAPK, PI3K/AKT and the 
IKK pathways, and results in reduced activity of 
the nuclear factors AP-1 and NF-κB and deficient 
IL-2 gene transcription, but there is elevated 
NFAT signalling in anergic cells [153]. Clonal 
anergy is an active process that requires new 
protein synthesis and is associated with an anergic 
gene expression profile that is characterized by 
increased expression of a number of E3 ubiquitin 
ligases including Cbl-b, Itch, Grail [154]. Recent 
studies have also identified that the induction of 
anergy is associated with induction of numerous 
negative regulators of TCR signalling including 
growth arrest and DNA-damage-inducible 45 β 
(Gadd45β), diacyglycerol kinase, caspase3, Traf6, 
Ikaros, Egr2, Egr3 and CREM (cyclic AMP 
response element modulator) [154-160]. Egr2 and 
Egr3 can regulate the expression of Cbl-b [159]. 
Deltex is induced during CD4+ T cell anergy 
mediated by treatment of cells with the calcium 
ionophore, ionomycin or treatment with CTLA-
4Ig which blocks delivery of costimulatory signals
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is a lot more to learn about the role of 
Notch in regulating B cell responses to antigen. T 
follicular helper (Tfh) cells play a critical role in 
initiating the germinal centre response in the 
spleen by directly regulating the activation of 
follicular B cells. At present there is nothing 
known about the role of Notch in Tfh cells and 
this will be an important area to explore with the 
use of conditional knockouts with receptors 
and/or ligands.  
 
CONCLUSIONS AND FUTURE PROSPECTS
Notch is an evolutionary conserved signalling 
pathway and over the last 15 years there has been 
a considerable advance in our knowledge about 
how Notch influences cell fate decisions and 
differentiation in a wide range of cell types in the 
immune system. The preeminent cell fate decisions 
regulated by Notch include the T/B cell fate 
decision in the thymus and the differentiation of 
marginal zone B cells in the periphery where the 
precise Notch receptor - ligand pairs have been 
unequivocally determined. The Notch ligands 
appear to have exclusive roles like that observed 
in other developmental systems, this is best 
observed in mature T cells in regulating the 
Th1/Th2 cell fate decision where Delta and 
Jagged ligands induce distinct responses but this 
response may depend on integration of signals 
from more than one Notch receptor. The general 
consensus of the studies suggests that Notch-
Notch ligand signals mediate an inductive signal 
to regulate cell fate specification. There does not 
appear to be any evidence for lateral inhibition 
having a role in regulating cell fate decisions in 
the thymus or in any other tissues in the immune 
system.  
The role of Notch signalling in the development 
of iTreg cells continues to receive some focus and 
this has important implications for therapeutic 
modulation of immune based diseases such as 
allergy, autoimmunity and transplantation tolerance.  
There is strong evidence for the role of Jagged 
ligands inducing iTreg differentiation in both 
mouse and human T cells, but exactly how these 
ligands are able to induce iTreg cells requires 
further dissection. Some studies indicate that 
ectopic expression of Notch ligands on APCs can 
direct iTreg differentiation while others suggest 
 
the recent BM cell migrants and have a surface 
phenotype (IgMhiIgD–CD21– CD23–) and they can 
develop into (IgM+IgD+CD21+ CD23+) T2 B cells.  
The T2 cells can further differentiate to become 
recirculating B cells and it was proposed that 
this population of cells may contain the MZ B 
precursors [169]. The signals that direct the MZ 
versus follicular B cell fate had been largely 
unknown but recent studies have provided 
convincing evidence that Notch signalling plays a 
crucial role in this decision process. 
Conditional deletion of either Notch2 or the 
downstream signalling molecule RBP-Jκ leads to 
the selective loss of MZ B cells in the spleen [71]. 
Conversely, the conditional deletion of Mint a 
negative regulator of Notch signalling leads to the 
preferential production of MZ B cells at the 
expense of B2 follicular cells [170]. Collectively 
these studies reveal that specification of the MZ B 
cell fate requires a canonical Notch signal that is 
mediated by Notch2 and RBP-Jκ and that this 
pathway can be inhibited by Mint. Jagged ligands 
do not play a role in the MZ B cell fate decision 
but rather Dll1 is the major ligand required for 
the MZ B cell fate decision [81]. It was recently 
shown that Dll1 is expressed on endothelial cells 
in the red pulp and marginal zone in the spleen 
and conditional deletion of Dll1 in B cells leads to 
the selective depletion of MZ B cells [53]. Lunatic 
and Manic Fringe appear to cooperate to modify 
Notch receptors on B cells to enhance the initial 
weak interaction between Notch2 and Dll1 [53]. 
Fringe modified receptors on B cells enhances 
precursor competition for Dll1 in defined niches 
and this directs the formation of marginal zone 
precursors and these can differentiate to become 
mature MZ B cells. 
Given the important role that Notch signalling has 
in the regulation of Th1/Th2 responses in vivo, it 
is interesting that relatively little is known about 
the role of Notch signalling in controlling humoral 
immune responses. A study by Santos showed that 
Dll1-Notch signalling in B cells could enhance the 
production of antibody secreting cells by naturally 
activated MZ B cells and B1 B cells [171]. 
Conversely suppression of Notch signalling by 
either conditional deletion of Notch1 or expression 
of the DNMAML1 could block enhancement of 
antibody secretion  in LPS activated B cells [171].
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Although Notch signalling appears to influence 
immune regulation it is interesting to note that 
many of the conditional knockouts of receptors, 
ligands or downstream signalling components do 
not develop significant autoimmune diseases that 
lead to perinatal death such as that observed with 
the loss of Foxp3 in Scurfy mice and in X-Linked 
Autoimmunity-Allergic Dysregulation (XLAAD)/ 
Immunodysregulation, polyendocrinopathy, and 
enteropathy, X-linked (IPEX) patients. This indicates 
that Notch signals are not required for the 
differentiation of the nTreg population and even 
though Notch signalling can influence immune 
regulation there must be sufficient checkpoints in 
place in the periphery to control cellular immune 
responses. It is going to be fascinating to see how 
the field develops in the next 10 years and perhaps 
Notch signalling could be targeted in therapeutic 
interventions in a range of immune mediated 
diseases. 
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